Next Phase Newsletter

The firm is a a small socially responsible VC firm focused specifically on ophthalmic investments. The firm’s purpose is investing in drugs, devices, and diagnostics that improve and preserve vision. The firm looks to identify and bring forward early stage investments with our deep knowledge of the space. The firm is currently allocating $100,000-$750,000 utilizing convertible notes in seed stage companies and equity in post seed stage companies. The firm is interested in co-investing as part of a syndicate. The firm is currently seeking new opportunities based in North America and Europe.

The firm specializes in early-stage investments in innovative ophthalmic diagnostic and treatment solutions. The firm seeks to invest in a broad range of technologies applicable to ophthalmology, including small molecule and biologic therapeutics, low- and high-risk medical devices, diagnostics, drug delivery, and software solutions. The firm would also consider generic drugs but with less interest. The firm considers companies at all stages, but prefers early stage projects with some clinical or other supporting data where it can add meaningful expertise outside of financial capital.

The firm seeks management teams formed by experienced entrepreneurs with track records of success and scientists with domain expertise in their field. The firm opportunistically seeks board seats on a deal-by-deal basis particularly in situations where they can add meaningful value.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A family office based in New York, NY is looking to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers companies that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A venture capital firm founded in 2020 is headquartered in Paris, France, with an additional office based in the USA. The firm is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities, but focuses on USA and Europe-based companies.

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic, but tends to stray away from cardiovascular and CNS indications.

The firm has no specific company or management team requirements,and seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Founded in 2015, a firm is headquartered in Beijing, managing three venture capital funds in RMB with a total of 1,400M RMB (~200M USD); And is still raising a fund in U.S. dollars of 50M~100M USD, with the confirmed limited partners from well-known Chinese big pharma. The firm has 24 portfolio companies, and is open to investing globally in the angel to series B round, with a focus on series A round. For therapeutics, the firm is interested in pre-clinical to phase III, mainly the pre-clinical stage. For each fund, Alwin Capital selects 10-15 companies to invest, and each investment ranging from 10MM RMB (1,420,000 USD) to 40MM RMB (5,700,000 USD); the rest of the fund will be used to invest the future rounds of those selected companies to help them grow.

The firm has a general interest in the early-stage life science technology assets, including therapeutics, diagnostics, medical devices, and digital health, especially MRA, Gene diagnostics, AI in healthcare, cell/gene therapy. The firm prefers projects in novel developing areas, but has less interest in technologies that are already in the field of very fierce competition, with big players already in.

The firm has no specific requirements for the Company & Management Team.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

The investment firm is a philanthropic venture firm established by a family office to accelerate the development of promising technologies for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments. The US-based firm makes 4-5 investments each year of approximately $1 million into privately-held companies worldwide at both the seed and early venture stages. The firm operates under an evergreen structure and has made 43 investments to date.

While the firm is focused on cardiovascular, neurovascular and metabolic diseases (e.g., diabetes, dyslipidemia and obesity), the firm invests across all technology sectors including biotech, medtech, diagnostics, and regenerative medicine. The firm looks to invest in companies where its investment will help move the company to a value inflection point necessary for the next and larger financing round.

The firm invests in technologies that have the potential for a clear impact on patient therapy and/or standard of care, an adequate level of IP protection, well-defined use of proceeds with quantifiable and achievable milestones, and a clear understanding of the next round of fundraising needs including size and likely sources.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm operates from many offices across the globe and has invested in hundreds of companies in a wide variety of sectors. Recently, the firm has been expanding their portfolio in the life science/healthcare sector, and is actively seeking early-stage opportunities. With over $1B AUM, the firm will typically invest up to $3M as an initial check, with a significant portion of their capital dedicated  to follow-on investments. The firm is open to global opportunities, with a focus on USA, Europe, and Asia.

The firm is interested in therapeutics, diagnostics, digital health, and life science tools. The firm’s interest areas also include industrial biotechnology, synthetic biology, and robotics. While the firm does not completely rule out medical device opportunities, they are not a priority for the firm. Within therapeutics, the firm will consider both single assets and platform technologies. In general, the firm is stage and indication agnostic.

The firm has no specific company or management team requirements and is open to working with all types of management teams. The firm can act as a lead, co-lead, or co-investor, and provides operational support for their portfolio companies to help them scale.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science specialist venture fund manager headquartered in Western Europe generally invests in preclinical to clinical-stage life science companies, primarily in the field of therapeutic drug development with products addressing high unmet medical need and complementing pharma pipelines. The firm deploys its capital with a geographic focus on Europe (~2/3 of investments) and North America (~1/3 of investments). Currently, the firm invests out of two new funds: one fund closed in 2021 is focusing on preclinical to early clinical-stage assets; and another fund closed in 2020 is focusing on clinical-stage assets, cross-over/IPO rounds, PIPE investments, etc. The typical investment per round is €15-25m for both funds.

The firm invests in preclinical to clinical-stage life science companies, primarily in the field of therapeutic drug development with products addressing high unmet medical need and complementing Pharma’s pipelines.

The firm seeks a company with a strong and experienced management team and/or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.